Zhejiang Ausun Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Zhejiang Ausun Pharmaceutical has a total shareholder equity of CN¥2.3B and total debt of CN¥300.3M, which brings its debt-to-equity ratio to 13.1%. Its total assets and total liabilities are CN¥3.0B and CN¥723.6M respectively. Zhejiang Ausun Pharmaceutical's EBIT is CN¥266.8M making its interest coverage ratio -9. It has cash and short-term investments of CN¥1.0B.
Key information
13.1%
Debt to equity ratio
CN¥300.33m
Debt
| Interest coverage ratio | -9x |
| Cash | CN¥1.03b |
| Equity | CN¥2.29b |
| Total liabilities | CN¥723.56m |
| Total assets | CN¥3.02b |
Recent financial health updates
No updates
Recent updates
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06Financial Position Analysis
Short Term Liabilities: 603229's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥686.3M).
Long Term Liabilities: 603229's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥37.3M).
Debt to Equity History and Analysis
Debt Level: 603229 has more cash than its total debt.
Reducing Debt: 603229's debt to equity ratio has increased from 4.5% to 13.1% over the past 5 years.
Debt Coverage: 603229's debt is well covered by operating cash flow (98.4%).
Interest Coverage: 603229 earns more interest than it pays, so coverage of interest payments is not a concern.